The firms said they are collaborating to facilitate genetic testing to support early diagnosis of GM1, a rare monogenic recessive lysosomal storage disease.
The drugmaker has a small molecule drug called venglustat under Phase II development for Parkinson's disease patients with a specific genetic mutation.
The companies are currently working together to commercialize their respective products including genetic tests for type 2 diabetes and gestational diabetes risk.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
